BioCryst Pharmaceuticals, Inc.

BCRX

US09058V1035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
5.32 ^USD	-0.37%		+19.55%	-11.19%

05-09	BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO	CI
05-07	JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating	MT

BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023

November 02, 2023 at 07:00 am

BioCryst Pharmaceuticals, Inc. announced that the company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million.

Latest news about BioCryst Pharmaceuticals, Inc.

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO	05-09	CI
JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating	05-07	MT
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	05-06	MT
BioCryst Pharmaceuticals Shares Jump After Q1 Beat	05-06	MT
Transcript : BioCryst Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 06, 2024	05-06
Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024	05-06	CI
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return	05-06	DJ
BioCryst Pharmaceuticals Secures Approval for Orladeyo in Brazil	04-17	MT
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency	04-17	CI
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM	03-12
Transcript : BioCryst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 26, 2024	02-26
BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows as Revenue Increases	02-26	MT
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-26	CI
Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Posts Q4 Revenue $93.4M, vs. Street Est of $90M	02-26	MT
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024	02-26	CI
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-26	CI
North American Morning Briefing : Traders Await Inflation Data This Week	02-26	DJ
BioCryst Launches Hereditary Angioedema Drug in Italy	02-20	MT
BioCryst Launches Orladeyo (Berotralstat) in Italy	02-19	CI
Transcript : BioCryst Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:00 PM	01-09
BioCryst Pharmaceuticals Sees FY23, FY24 Orladeyo Sales Topping Prior Forecast; Eyes 2024 Operating Profit	01-05	MT
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	01-05	CI
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)	12-19	CI
Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023	12-01	CI

Chart BioCryst Pharmaceuticals, Inc.

Duration

Period

More charts

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Citizens JMP Life Sciences Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for BioCryst Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.32 USD

Average target price

14 USD

Spread / Average Target

+163.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOCRYST PHARMACEUTICALS, INC.	-11.19%	1.1B
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs